1. Ferlay J, Soerjomataram I, Dikshit R, Eser S, Mathers C, Rebelo M, et al. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer. 2015; 136:E359–86.
2. Jung KW, Won YJ, Oh CM, Kong HJ, Lee DH, Lee KH, et al. Cancer statistics in Korea: incidence, mortality, survival, and prevalence in 2014. Cancer Res Treat. 2017; 49:292–305.
3. Jun JK, Choi KS, Jung KW, Lee HY, Gapstur SM, Park EC, et al. Effectiveness of an organized cervical cancer screening program in Korea: results from a cohort study. Int J Cancer. 2009; 124:188–193.
4. Basu P, Ponti A, Anttila A, Ronco G, Senore C, Vale DB, et al. Status of implementation and organization of cancer screening in The European Union Member States-Summary results from the second European screening report. Int J Cancer. 2018; 142:44–56.
5. Suh M, Song S, Cho HN, Park B, Jun JK, Choi E, et al. Trends in participation rates for the National Cancer Screening Program in Korea, 2002–2012. Cancer Res Treat. 2017; 49:798–806.
6. Szarewski A, Cadman L, Mesher D, Austin J, Ashdown-Barr L, Edwards R, et al. HPV self-sampling as an alternative strategy in non-attenders for cervical screening - a randomised controlled trial. Br J Cancer. 2011; 104:915–920.
7. Waller J, Bartoszek M, Marlow L, Wardle J. Barriers to cervical cancer screening attendance in England: a population-based survey. J Med Screen. 2009; 16:199–204.
8. Virtanen A, Nieminen P, Niironen M, Luostarinen T, Anttila A. Self-sampling experiences among non-attendees to cervical screening. Gynecol Oncol. 2014; 135:487–494.
9. Mayrand MH, Duarte-Franco E, Rodrigues I, Walter SD, Hanley J, Ferenczy A, et al. Human papillomavirus DNA versus Papanicolaou screening tests for cervical cancer. N Engl J Med. 2007; 357:1579–1588.
10. Sultana F, Mullins R, English DR, Simpson JA, Drennan KT, Heley S, et al. Women's experience with home-based self-sampling for human papillomavirus testing. BMC Cancer. 2015; 15:849.
11. Snijders PJ, Verhoef VM, Arbyn M, Ogilvie G, Minozzi S, Banzi R, et al. High-risk HPV testing on self-sampled versus clinician-collected specimens: a review on the clinical accuracy and impact on population attendance in cervical cancer screening. Int J Cancer. 2013; 132:2223–2236.
12. Braz NS, Lorenzi NP, Sorpreso IC, Aguiar LM, Baracat EC, Soares-Júnior JM. The acceptability of vaginal smear self-collection for screening for cervical cancer: a systematic review. Clinics (Sao Paulo). 2017; 72:183–187.
13. Pathak N, Dodds J, Zamora J, Khan K. Accuracy of urinary human papillomavirus testing for presence of cervical HPV: systematic review and meta-analysis. BMJ. 2014; 349:g5264.
14. Kitchener HC, Owens GL. Urine testing for HPV. BMJ. 2014; 349:g5542.
15. Tanzi E, Bianchi S, Fasolo MM, Frati ER, Mazza F, Martinelli M, et al. High performance of a new PCR-based urine assay for HPV-DNA detection and genotyping. J Med Virol. 2013; 85:91–98.
16. Gök M, van Kemenade FJ, Heideman DA, Berkhof J, Rozendaal L, Spruyt JW, et al. Experience with high-risk human papillomavirus testing on vaginal brush-based self-samples of non-attendees of the cervical screening program. Int J Cancer. 2012; 130:1128–1135.
17. Bosgraaf RP, Ketelaars PJ, Verhoef VM, Massuger LF, Meijer CJ, Melchers WJ, et al. Reasons for non-attendance to cervical screening and preferences for HPV self-sampling in Dutch women. Prev Med. 2014; 64:108–113.
18. Kwak MS, Choi KS, Spring BJ, Park S, Park EC. Predicting the stages of adoption of cervical cancer screening among Korean women. Prev Med. 2009; 49:48–53.
19. Park B, Choi KS, Lee YY, Jun JK, Seo HG. Cancer screening status in Korea, 2011: results from the Korean National Cancer Screening Survey. Asian Pac J Cancer Prev. 2012; 13:1187–1191.
20. Abulizi G, Abulimiti T, Li H, Abuduxikuer G, Mijiti P, Zhang SQ, et al. Knowledge of cervical cancer and Pap smear among Uyghur women from Xinjiang, China. BMC Womens Health. 2018; 18:21.
21. Giorgi Rossi P, Marsili LM, Camilloni L, Iossa A, Lattanzi A, Sani C, et al. The effect of self-sampled HPV testing on participation to cervical cancer screening in Italy: a randomised controlled trial (ISRCTN96071600). Br J Cancer. 2011; 104:248–254.
22. Gök M, Heideman DA, van Kemenade FJ, Berkhof J, Rozendaal L, Spruyt JW, et al. HPV testing on self collected cervicovaginal lavage specimens as screening method for women who do not attend cervical screening: cohort study. BMJ. 2010; 340:c1040.
23. Hussain S, Bharadwaj M, Nasare V, Kumari M, Sharma S, Hedau S, et al. Human papillomavirus infection among young adolescents in India: impact of vaccination. J Med Virol. 2012; 84:298–305.
24. Ma'som M, Bhoo-Pathy N, Nasir NH, Bellinson J, Subramaniam S, Ma Y, et al. Attitudes and factors affecting acceptability of self-administered cervicovaginal sampling for human papillomavirus (HPV) genotyping as an alternative to Pap testing among multiethnic Malaysian women. BMJ Open. 2016; 6:e011022.
25. Verdoodt F, Jentschke M, Hillemanns P, Racey CS, Snijders PJ, Arbyn M. Reaching women who do not participate in the regular cervical cancer screening programme by offering self-sampling kits: a systematic review and meta-analysis of randomised trials. Eur J Cancer. 2015; 51:2375–2385.
26. Haguenoer K, Sengchanh S, Gaudy-Graffin C, Boyard J, Fontenay R, Marret H, et al. Vaginal self-sampling is a cost-effective way to increase participation in a cervical cancer screening programme: a randomised trial. Br J Cancer. 2014; 111:2187–2196.
27. Greiner KA, Daley CM, Epp A, James A, Yeh HW, Geana M, et al. Implementation intentions and colorectal screening: a randomized trial in safety-net clinics. Am J Prev Med. 2014; 47:703–714.
28. Arbyn M, Castle PE. Offering self-sampling kits for HPV testing to reach women who do not attend in the regular cervical cancer screening program. Cancer Epidemiol Biomarkers Prev. 2015; 24:769–772.
29. Karjalainen L, Anttila A, Nieminen P, Luostarinen T, Virtanen A. Self-sampling in cervical cancer screening: comparison of a brush-based and a lavage-based cervicovaginal self-sampling device. BMC Cancer. 2016; 16:221.
30. Hwang SH, Shin HY, Lee DO, Sung NY, Lee B, Lee DH, et al. A prospective pilot evaluation of vaginal and urine self-sampling for the Roche cobas 4800 HPV test for cervical cancer screening. Sci Rep. 2018; 8:9015.
31. Asciutto KC, Henningsson AJ, Borgfeldt H, Darlin L, Borgfeldt C. Vaginal and urine self-sampling compared to cervical sampling for HPV-testing with the cobas 4800 HPV test. Anticancer Res. 2017; 37:4183–4187.
32. Lim MC, Lee DH, Hwang SH, Hwang NR, Lee B, Shin HY, et al. Comparison of the Abbott RealTime High Risk HPV test and the Roche cobas 4800 HPV test using urine samples. J Virol Methods. 2017; 243:74–79.